Gilead Sciences Japan, Inc.
GPTKB entity
Properties (46)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:awards |
industry recognition
innovation awards |
| gptkbp:clinicalTrials |
ongoing studies
completed studies |
| gptkbp:collaborations |
academic institutions
biotech companies |
| gptkbp:communityEngagement |
patient support programs
healthcare_professional_education |
| gptkbp:corporateSocialResponsibility |
sustainability initiatives
access to medicines programs |
| gptkbp:employees |
approximately 200
|
| gptkbp:financialPerformance |
revenue growth
market share increase |
| gptkbp:focusArea |
antiviral drugs
|
| gptkbp:founded |
2001
|
| gptkbp:headquarters |
gptkb:Tokyo,_Japan
|
| https://www.w3.org/2000/01/rdf-schema#label |
Gilead Sciences Japan, Inc.
|
| gptkbp:investmentFocus |
infrastructure development
research funding |
| gptkbp:leadership |
CEO
executive team |
| gptkbp:market |
gptkb:Japan
|
| gptkbp:parentCompany |
gptkb:Gilead_Sciences,_Inc.
|
| gptkbp:partnerships |
various healthcare organizations
|
| gptkbp:products |
HIV medications
Hepatitis C treatments |
| gptkbp:regulatoryCompliance |
gptkb:Japanese_Pharmaceuticals_and_Medical_Devices_Agency
|
| gptkbp:research_areas |
oncology
inflammation infectious diseases |
| gptkbp:researchAndDevelopment |
biopharmaceuticals
|
| gptkbp:strategicGoals |
foster innovation
promote diversity and inclusion improve healthcare outcomes optimize operational efficiency strengthen partnerships support public health initiatives develop new therapies engage with stakeholders leverage technology increase market presence expand product portfolio enhance corporate reputation enhance patient access |
| gptkbp:website |
www.gilead.com
|